Intellipharmaceutics International Inc. was a big mover last session, as the company saw its shares rise around 19% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $2.02 to $2.22 in the past one-month time frame.

The company has seen no positive or negative estimate revision in the past 30 days. But its Zacks Consensus Estimate moved higher over the same timeframe. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
 
Intellipharmaceutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.

Intellipharmaceutics International Inc. Price

Intellipharmaceutics International Inc. Price | Intellipharmaceutics International Inc. Quote

A better-ranked stock in the Medical – Drugs industry is Aratana Therapeutics, Inc. , which holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Is IPCI going up? Or down? Predict to see what others think: Up or Down

Today's Stocks from Zacks' Hottest Strategies                                                                                                                                                                                                                                                                                                                                                                                                                    

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.                                                                                                                                                                                                                                                                                                                                                         
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>